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INTRODUCTION
As the first functional organ during embryonic development, the
heart is formed through a complex series of multi-lineage cell
interactions that coordinate proliferation, migration and
differentiation (Olson, 2006; Srivastava, 2006). The requirement
for a highly regulated balance of heterotypic signaling events is
evident after one or more genes are lost, leading to dire
consequences for cardiac development. In fact, congenital heart
malformations account for nearly one-third of all major congenital
defects, which remain the leading cause of infant mortality in the
United States (Mathews and MacDorman, 2011; van der Linde et
al., 2011). Thus, a concrete understanding of the regulatory
circuitry of interactions during cardiac development is essential.
Over the last two decades, significant strides have been made
towards accomplishing this goal; however, the picture is far from
complete.
Several congenital vascular diseases are associated with
mutations in the Notch signaling pathway, including Alagille
syndrome (AGS), cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy (CADASIL) and
calcific aortic valve disease (Gridley, 2010; High and Epstein,
2008; MacGrogan et al., 2011; Nemir and Pedrazzini, 2008; Penton
et al., 2012). The initial link between the Notch ligand jagged 1
(Jag1) and heart development was established in 1997, with the
simultaneous discovery by two groups that AGS was caused by
mutations in the human JAG1 gene (Penton et al., 2012). AGS is
an autosomal dominant multisystem disorder that leads to paucity
of intrahepatic bile ducts, as well as cardiac, skeletal, renal, facial
and ocular abnormalities. Subsequently, it was found that although
the majority of AGS patients had mutations in JAG1, a small subset
of individuals harbored mutations in the gene encoding the
NOTCH2 receptor (McDaniell et al., 2006).
Over the last decade, many investigations have focused on
mapping JAG1 mutations and determining its expression patterns
to understand better the function of this gene in the context of the
disease (Bauer et al., 2010; Crosnier et al., 2000; Eldadah et al.,
2001; Gridley, 2010; High and Epstein, 2008; Jones et al., 2000;
Krantz et al., 1999; Loomes et al., 1999; McDaniell et al., 2006;
Raas-Rothschild et al., 2002; Rutenberg et al., 2006). Elegant
studies using cell-specific loss of function have revealed the
involvement of Jag1 in the closure of the ductus arteriosus and in
several aspects of cardiac morphogenesis (Feng et al., 2010; High
et al., 2009; Manderfield et al., 2012). Particularly during heart
development, Jag1 is expressed in the coronary arteries, secondary
heart field and neural crest cells (de la Pompa and Epstein, 2012;
Penton et al., 2012). Inactivation of the gene within these
compartments yields cardiac outflow and aortic arch artery defects
resulting in lethality by embryonic day (E) 10.5 (High et al., 2009;
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SUMMARY
The Notch signaling pathway is an important contributor to the development and homeostasis of the cardiovascular system. Not
surprisingly, mutations in Notch receptors and ligands have been linked to a variety of hereditary diseases that impact both the
heart and the vasculature. In particular, mutations in the gene encoding the human Notch ligand jagged 1 result in a multisystem
autosomal dominant disorder called Alagille syndrome, which includes tetralogy of Fallot among its more severe cardiac pathologies.
Jagged 1 is expressed throughout the developing embryo, particularly in endothelial cells. Here, we demonstrate that endothelial-
specific deletion of Jag1 leads to cardiovascular defects in both embryonic and adult mice that are reminiscent of those in Alagille
syndrome. Mutant mice display right ventricular hypertrophy, overriding aorta, ventricular septal defects, coronary vessel
abnormalities and valve defects. Examination of mid-gestational embryos revealed that the loss of Jag1, similar to the loss of Notch1,
disrupts endothelial-to-mesenchymal transition during endocardial cushion formation. Furthermore, adult mutant mice exhibit
cardiac valve calcifications associated with abnormal matrix remodeling and induction of bone morphogenesis. This work shows
that the endothelium is responsible for the wide spectrum of cardiac phenotypes displayed in Alagille Syndrome and it demonstrates
a crucial role for Jag1 in valve morphogenesis.
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Manderfield et al., 2012). The defects, however, do not recapitulate
those displayed by patients with AGS or aortic valve disease. It is
likely that the severe cardiac abnormalities displayed by these
murine models might also result in lethality in humans.
To examine the contribution of endothelial Jag1 at later
developmental time points than those evaluated previously, we
used a VE-Cadherin-Cre-mediated excision of the gene. The
resultant Jag1 mutant mice displayed a spectrum of cardiac defects
that were highly reminiscent of those present in AGS, including
ventricular septal defects (VSD), overriding aorta, right ventricular
hypertrophy, valve malformations and stenosis. Through a
combination of genetic, histological and organotypic ex vivo
studies, we showed that the loss of Jag1 in the endothelium leads
to a blockage of endothelial-to-mesenchymal transformation
(EndMT), an essential step in formation of the atrioventricular
(AV) valves and septum intermedium. In addition, at later stages of
heart development, Jag1 is required for proper valve remodeling.
Absence of Jag1 results in myxomatous valves owing to the
accumulation of uncleaved versican. Furthermore, 50% of mutant
mice developed valve calcifications with accumulation of bone
between 5 and 13 months of age. These findings indicate that the
cardiac defects manifested in AGS and other valve-specific defects
are largely endothelial derived and are rooted in defective Jag1
signaling during early embryonic development.
MATERIALS AND METHODS
Animals
VE-Cadherin-Cre (Alva et al., 2006), Jag1flox/flox (Mancini et al., 2005) and
Notch1flox/flox (Radtke et al., 1999) mice were previously described and bred
for six generations on a C57BL/6J background. These mice were also
crossed to R26R (Soriano, 1999) or TNR1 Notch reporter mice (Duncan
et al., 2005). Embryos were collected using timed matings. PCR analysis
on genomic DNA from embryos or tails was used for genotyping.
Tissue collection and imaging
Standard protocols for staining, immunocytochemistry and imaging were
used with paraformaldehyde- or glutaraldehyde-fixed tissues (Alva et al.,
2006). -Galactosidase staining was performed as previously described
(Alva et al., 2006). Standard protocols for Hematoxylin and Eosin (H&E),
Nuclear Fast Red, Alizarin Red S and von Kossa staining were used for
cardiac slides. Antibodies used were: anti-rat jagged 1 (R&D Systems;
1:25), anti-PECAM1 (gift of Joseph A. Madri, Yale, New Haven, CT,
USA; 1:250), anti-PECAM1 (BD Pharmingen; 1:250), anti- smooth
muscle actin-FITC (SMA; Sigma; 1:800), anti-VersicanGAG
(Chemicon; 1:100) and anti-versican V0/V1 (DPEAAE; Thermo Scientific;
1:50). For non-fluorescent immunostaining, tissues were incubated with
primary antibodies and biotinylated secondary antibodies (Jackson
ImmunoResearch Laboratories), and treated with Vectastain ABC Kit
reagents (Vector Labs) followed by DAB substrate (Vector Labs). Alexa
Fluor-conjugated (Invitrogen) or FITC-conjugated (Jackson
ImmunoResearch Laboratories) fluorescent secondary antibodies were used
and DAPI (Invitrogen; 1:1000) or TOPRO-3 (Molecular Probes; 1:300)
were used for counterstaining. Tissues were analyzed using a Zeiss LSM
multiphoton microscope (Carl Zeiss AG) and image processing was carried
out using Adobe Photoshop CS5 (Adobe Systems).
Cardiac physiology and imaging
Mice were anesthetized with 2% isofluorane, and heart rate and body
temperature were monitored during Doppler and 2D imaging. For micro-
computed tomography (CT) imaging, hearts were perfused with 1 PBS,
fixed with 4% paraformaldehyde, stained with a contrast agent, and
scanned at 10 m isometric voxel resolution at 200 mseconds exposure
time (volumetric CT scanner CT40 from ScanCo Medical, Numira
Biosciences, Salt Lake City, UT, USA; Virtual Histology). Doppler and 2D
imaging of the parasternal long-axis and short axis were performed by
echocardiography using a Vevo 770 Imaging System (Visual Sonics,
Toronto, Canada) that was equipped with the RMV-707B transducer (30
Mhz 12.7 mm focal length), with the placement of the Doppler probe at
65° with coronal plane as described (Liao et al., 2001).
Cardiac explants
E9.5 atrioventricular cardiac cushions (20-28 somites) were dissected and
explanted as described (Camenisch et al., 2002; Runyan and Markwald,
1983). N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl
ester (DAPT; 10 M or 50 M, diluted in DMSO) or 0.2% DMSO
(controls) was added to wild-type explants. Media, with/without DAPT and
DMSO, was changed daily. Explants were photographed in 12-hour
increments. Samples were stained with anti-SMA, anti-PECAM1 and
TOPRO3 and imaged. For treatment with -secretase inhibitors, wild-type
explants were adhered to type I collagen gels for a minimum of 6 hours
before adding DAPT or DMSO. Two independent observers counted total
nuclei embedded within the collagen matrix in selected areas and the
percentage of transformed mesenchymal cells (SMA+, PECAM1–
expression). P was calculated using Student’s two-tailed t-test for paired
comparisons and one-way ANOVA with the Bonferroni correction was
applied when analyzing multiple (three) groups.
Quantitative real time PCR
Postnatal day (P) 10 mouse outflow tract (OFT) and AV valves were
isolated under a dissecting microscope. Total RNA from OFT and AV
valves was purified using the RNeasy Mini Kit (QIAGEN, Valencia, CA,
USA). Complementary DNA synthesis from 15-25 ng of total RNA was
performed using SuperScript III (Invitrogen). Quantitative RT-PCR was
then performed on a DNA Engine Opticon 2 Real-Time Cycler PCR (MJ
Research; Biorad, Hercules, CA, USA) using the RT2 SYBR Green qPCR
Master Mix (SABiosciences; QIAGEN). Primer sequences are listed in
supplementary material Table S1. Results were analyzed with MJ Opticon
Monitor Analysis software Version 3.1 (MJ Research; Biorad). Each
reaction was run in duplicate and normalized with the housekeeping gene
Hprt. Data are presented relative to mean CT of wild-type animals. P was
calculated using the Student-Fisher test.
FACS, western blot analysis and immunoprecipitation
Endothelial cells were fluorescence-activated cell sorted (FACS) from
E12.5, E13.5, E15.5, E17.5 and P10 J1WT and J1ECKO embryos using anti-
PECAM antibodies, as previously described (Zovein et al., 2010). All
samples were stained for viability with 7-AAD (BD Pharmingen) and
analyzed on a FACSCaliber with the appropriate isotype controls.
Endothelial cell protein lysate from J1WT and J1ECKO embryos were
separately pooled for each time point and quantified for protein
concentration (DC protein, BioRad). Then samples were pre-cleared with
beads bound to secondary antibodies and incubated overnight with 
anti-Jag1 (Santa Cruz Biotechnology) (1:800). Recovery of the
immunocomplexes and western blot were carried out as previously
described (Chen et al., 2010).
RESULTS
Temporal loss of Jag1 after endothelial-specific
deletion
We have previously reported that an endothelial-specific deletion of
Jag1 using a VE-Cadherin-Cre line, termed Jag1 endothelial cell
knockout (J1ECKO) mice, yielded viable mutants with normal bile
duct development, but defective vascular smooth muscle cell
recruitment (Hofmann et al., 2010; Scheppke et al., 2012). By
contrast, previous reports of Jag1-specific endothelial deletion
resulted in embryonic lethality at E10.5 (Benedito et al., 2009; High
et al., 2008). We suspected that these differences might relate to the
timing/efficiency of deletion conveyed by each Cre line. In fact,
evaluation of temporal loss of Jag1 in J1ECKO mice demonstrated
sporadic loss of the protein by E10.5 (Fig. 1A, arrowheads). By P0,
expression of Jag1 protein was largely lost in the endothelium of the
dorsal aorta (Fig. 1A, arrowheads), but was retained within the
smooth muscle cells of the vascular wall (Fig. 1A, arrows).











To quantify more rigorously Jag1 changes in J1ECKO mice, we
performed western blot analysis on lysates from endothelial cells
isolated at different stages of development (Fig. 1B). By E12.5,
~60% of Jag1 protein was lost, with a more significant decrease
soon after at E13.5 (close to 90%), compared with littermate
controls (Fig. 1B). The use of the Rosa26;lacZ reporter line
(R26R) (Soriano, 1999) further revealed the temporal activity of
VE-Cadherin-Cre at the cellular level and confirmed varying
levels of Cre recombination at E10.5. Two extreme examples are
shown in Fig. 1C. In mice with high recombination (Fig. 1C,
upper panel), endothelial cells of major arteries were almost
completely -galactosidase-positive (Fig. 1C, arrows), with veins
slightly less so (Fig. 1C, arrowheads). The endothelial cells (Fig.
1C, black arrows) and endothelial-derived mesenchymal cells of
the cardiac cushions (Fig. 1C, red arrows) also showed a high
degree of recombination. By contrast, mice with low levels of
Cre recombination at a similar time point, exhibited only a few
-galactosidase-positive cells in the vessels and cardiac cushions
of the heart (Fig. 1C, lower panels, black arrows). In fact, the
majority of the arterial and venous endothelium, as well as the
endocardium, was -galactosidase negative (Fig. 1C, black
arrowheads), whereas few -galactosidase-positive mesenchymal
cells (Fig. 1C, red arrows) were present alongside -
galactosidase-negative cells (Fig. 1C, red arrowheads). The
variable penetrance of this particular VE-Cadherin-Cre in early
development (E10.5), as well as the mixed C57Bl6 F6
background of the mice, explain the wide range of lethality
observed in J1ECKO mice, reconcile these findings with previous
groups and, more importantly, provide an opportunity to explore
the requirement for Jag1 in endothelial cells at different
developmental stages and to determine the relevance of Jag1
deletion.
Morphology and physiological analysis of adult
J1ECKO hearts revealed cardiac defects
Although viable J1ECKO mice were frequently recovered, several
pups and adult mice succumbed to sudden death. A closer
examination of surviving adult J1ECKO hearts showed that mutant
mice displayed a range of cardiac anomalies (Fig. 2). This was
consistent with the mosaic deletion pattern of Jag1 early in
development and mimicked the cardiac components of AGS.
However, other organs frequently impacted by AGS, including the
liver, eye, kidney and vertebrae, were not affected (Hofmann et al.,
2010) (data not shown).
Common features in many adult J1ECKO animals were
macroscopic aberrations in heart morphology, including thin or
disorganized coronary vessels (Fig. 2A, arrowheads), dilation noted
near the apex of the heart (Fig. 2A, arrows) and abnormal
positioning of the aorta and pulmonary trunk (not shown).
Echocardiographic evaluations of a sampling of adult mice showed
that J1ECKO mice had increased systolic blood velocity with severe
regurgitation at the pulmonic valve, compared with Cre-negative
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Fig. 1. Deletion of Jag1 in the endothelium. (A) Jag1 immunostaining (green) in the endothelium (red) of J1WT and J1ECKO mice. Mosaic Jag1
expression in E10.5 J1ECKO vessels compared with J1WT mice, with areas of Jag1 loss (arrowheads) adjacent to areas of Jag1 expression (arrows). By
P0, endothelial Jag1 deletion was highly penetrant (arrowheads) in J1ECKO mice, whereas Jag1 was maintained in veins and some smooth muscle
cells (arrows). (B) Western blot on fluorescence-activated cell sorting (FACS)-isolated endothelial cells from J1WT and J1ECKO embryos at progressive
developmental stages showed decreases in Jag1 levels over time in J1ECKO mice compared with J1WT. Tubulin levels were used as loading controls.
Several faint lower bands in embryonic J1ECKO samples were degradation/processing fragments not seen in other equivalent samples. (C) Evaluation
of VE-Cadherin-Cre activity at E10.5 revealed animals with high (upper panels) and low (lower panels) recombination, as shown by -galactosidase
staining (blue). Arrows indicate recombined cells and arrowheads non-recombined endothelium. Cardiac cushions at high magnification show both
recombined (red arrows) and non-recombined (red arrowheads) mesenchymal cells resulting from EndMT cells. a, atrium; v, ventricle. Scale bars: 50












littermates, indicating valve stenosis (Fig. 2B, white arrows).
Mutants also exhibited significant increases in right ventricle area
and had right atrial and ventricular hypertrophy, noted with the use
of cardiac micro-computed tomography (CT) imaging (Fig.
2B,C). Thickening of the right ventricular wall was probably a
compensation due to the increased pressure load of the right
ventricle caused by pulmonary outflow tract narrowing or defective
valves, common in AGS patients (McElhinney et al., 2002; Otto,
2009). Additionally, CT imaging revealed greater density and
excessive branching of coronary vessels in many of the J1ECKO
hearts (Fig. 2D,E), as would be expected for a Notch loss-of-
function phenotype, even though the data did not reach
significance.
Embryonic and neonatal cardiac defects in J1ECKO
mice
Evaluation of J1ECKO hearts from embryos and neonates was also
consistent with AGS-related cardiac defects, including many
hallmarks of tetralogy of Fallot (TOF): VSDs, overriding aorta and
right ventricular hypertrophy, as well as valve pathology (Table 1;
Fig. 3). Upon gross evaluation, the morphology of neonatal J1ECKO
hearts was often striking, with anomalies in the structure (Fig. 3A,
arrows) and patterning of the coronary vasculature, including
fragility and hemorrhaging (Fig. 3A, arrowheads), as well as
outflow tract defects (Fig. 3B, dotted lines).
Histological analysis revealed VSDs (Fig. 3C,D, arrows) and
large, hyperplastic (myxomatous) valves in J1ECKO mice (Fig. 3C,
asterisk). The ventricular septum of mice typically divides the
ventricles at E13.5; however, examination of embryonic J1ECKO
hearts showed an incomplete septum at E14.5 (Fig. 3D, arrow).
Bulges near the valve annulus were seen in some neonatal J1ECKO
mice with otherwise normal valve leaflet development (Fig. 3E,
arrow). Macroscopic analysis of 46 embryonic or neonatal J1ECKO
mice showed that one or more cardiac abnormalities were present
in 47.8% of the mice evaluated, with overriding aorta being the
most common defect (Table 1).
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Fig. 2. Cardiac defects in adult Jag1 endothelial mutants. (A) J1ECKO mice demonstrated morphological defects in the adult heart. Hearts from
mutant mice frequently exhibited defective coronary vessel branching (arrowheads) and abnormal heart structure near the apex (arrows),
suggesting dilation or right ventricular hypertrophy (arrows) (n=20). (B) Representative 2D echo and Doppler images of adult male mice, measured
near the right ventricular outflow tract, showed severe regurgitation at the pulmonary semilunar valve and an increase in systolic blood velocity
during right ventricular ejection in J1ECKO hearts. Note different scales of velocity (white arrows) in J1WT (cm/second) and J1ECKO (m/second)
measurements. The lower images of the same panel display a left parasternal transverse section with 2D measurement of adult hearts,
demonstrating an increase in the right ventricular chamber (yellow dotted line and yellow arrow) and a decrease in the left ventricular chamber (red
dotted line and red arrow) in J1ECKO mice (n=6) compared with J1WT (n=6). Measurement of ventricular chamber area at diastolic demonstrated a
significant increase in the size of J1ECKO right ventricles (*P=0.024). (C) CT imaging of adult J1WT and J1ECKO hearts showed right ventricular
hyperplasia in mutants, as per measurements of the right ventricular wall (red line between a and b). J1ECKO hearts also showed enlarged right atria
(arrows). (D) Additional CT imaging of adult J1ECKO hearts revealed increased coronary vessel density in many mice. (E) Quantification of vessel
number according to vessel diameter of J1ECKO and J1WT hearts using CT (n=11). lv, left ventricle; ra, right atrium; rv, right ventricle. Error bars











Defects in endocardial cushion formation in J1ECKO
and N1ECKO mice
Cushion development requires a specialized form of epithelial-to-
mesenchymal transition (EMT) called endothelial-to-mesenchymal
transformation (EndMT), a process that is initiated in the mouse at
E9.5 (de la Pompa and Epstein, 2012). The events associated with
EndMT include: endocardial cell delamination from a flattened
monolayer, transformation of endothelial cells into mesenchymal
cells, migration and invasion into the cardiac jelly, and rapid
proliferation (Armstrong and Bischoff, 2004; Eisenberg and
Markwald, 1995; Person et al., 2005; Schroeder and Listgarten,
2003). Given the phenotype of J1ECKO mice, we sought to examine
the hearts of J1ECKO mice in greater detail, and compared them with
VE-Cadherin-Cre; Notch1flox/flox mice (N1ECKO) mice during
cardiac cushion remodeling at E10.5 (Fig. 4).
The AV cushions of J1ECKO hearts at E10.5 showed rounded
endocardial-derived cells (Fig. 4B,C, arrowheads) that
accumulated at the cushion interface (Fig. 4B,C, red arrows) and
less dense, hypoplastic areas present within the cushions (Fig.
4B,C, open arrows). This was in contrast to the high
transformation of cushions from VE-Cadherin-Cre;R26R hearts
at E10.5 (Fig. 4A). Overall, EndMT was at least temporally
delayed in the J1ECKO hearts, with fewer transformed
mesenchymal cells present in the AV cushions.
Consistent with published findings on global deletion of Notch1
or pharmacological inactivation of the Notch pathway (Fischer et
al., 2007; Timmerman et al., 2004), endothelial deletion of Notch1
in N1ECKO hearts also resulted in EndMT arrest (Fig. 4D) and
phenocopied the J1ECKO hearts, with rounded cells present at the
cushion interface (Fig. 4D, red arrows) and areas with few
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Table 1. Macroscopic embryonic and neonatal cardiac defects in J1ECKO mice
Number of animals Percentage of J1ECKO mice affected
J1ECKO animals with at least one cardiac defect 22 47.8
Overriding aorta 14 30.4
Abnormal coronary vessels 6 13
Enlarged heart 3 6.5
Enlarged right ventricle 2 4.3
Abnormal outflow tract 1 2.2
Non-obvious macroscopic defect 24 52.2
Total number of J1ECKO animals examined 46 –
Some form of cardiac defect, including overriding aorta, abnormal coronary vessel patterning, enlarged heart and enlarged right ventricle, was shown in 47.8% of
embryonic and neonatal J1ECKO mice from 16 litters. Overriding aorta was the most common macroscopic defect affecting these mutant mice.
Fig. 3. AGS-related cardiac defects in embryonic and neonatal J1ECKO mice. (A-C) Light microscopy of the back (A) and front (B) of neonatal
J1WT and J1ECKO hearts (n≥20). (A) Compared with J1WT mice, hearts of P0 J1ECKO mice displayed a variety of cardiac defects, such as abnormal
morphology and increased atrial and ventricular size (A, arrows), in addition to dilated, hemorrhaging cardiac vessels (A, arrowheads). (B) P1 hearts
of J1WT and J1ECKO mutants, with corresponding H&E-stained histological sections of the respective hearts below (C). An overriding aorta was noted
in the J1ECKO heart (B, arrow). Dotted lines delineate great vessels and highlight outflow tract defects. (C) Histological sections of these J1ECKO
hearts, with high magnification images below, revealed ventricular septal defects (arrows) and hypertrophic valves (asterisk). (D) Light microscopy of
-galactosidase-stained histological sections of E14.5 VE-Cadherin-Cre;Rosa26R wild-type and J1ECKO hearts revealed VSDs in the mutant hearts (D,
arrow) 24 hours after the septum normally closes, as seen in the wild-type heart (D). (E) Large bulges were occasionally found near the valve
annulus between the left atria and ventricle in P5 J1ECKO H&E-stained hearts (E, arrow). ao, aorta; la, left atrium; lv, left ventricle; pa, pulmonary











transformed mesenchymal cells (Fig. 4D, open arrows). Similar to
the AV cushions, the OFT or semilunar cushions, which form the
aortic and pulmonary valves, also showed delayed EndMT in both
the J1ECKO and N1ECKO mice (Fig. 4E-H). Some -galactosidase-
negative mesenchymal cells were present in the cardiac jelly of
J1ECKO mice, demonstrating that EndMT was able to occur in areas
without VE-Cadherin-Cre expression (Fig. 4F,G, arrows).
However, in regions in which endocardial cells were -
galactosidase positive, EndMT was disrupted (Fig. 4F-H, open
arrows). As mentioned previously, the survival of the J1ECKO mice
and the wide range in phenotypes can be explained by the slow
penetration of VE-Cadherin-Cre recombination at crucial times
during EndMT (Fig. 1B).
J1ECKO hearts demonstrate impaired EndMT in
vitro due to a loss of Notch signaling
To investigate the cellular events associated with the loss of Jag1, we
explanted cardiac cushions from the AV canal of E9.5 J1ECKO mice
for 48-72 hours and evaluated EndMT as previously described
(Eisenberg and Markwald, 1995; Lakkis and Epstein, 1998). AV
explants from J1WT mice had outgrowths of elongated SMA (Acta2
– Mouse Genome Informatics)-positive cells that invaded the
collagen gel, indicative of endocardial cells transforming into
mesenchymal cells (Fig. 5A, arrows). Loss of Jag1 in the
endothelium resulted in a persistence of Pecam1-positive endocardial
cells (Fig. 5A, arrowheads) and SMA-negative cells
(untransformed) that grew out of the explant, but remained on the
surface of the collagen gel as a sheet (Fig. 5A, bracket). Less than
half of J1ECKO endocardial cells were transformed (Fig. 5B). Thus,
the loss of only endothelial Jag1 resembled blockade of all Notch
reporter signaling via the -secretase inhibitor N-[N-(3,5-
difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT)
in wild-type cushions (Fig. 5A,C) (Timmerman et al., 2004). EndMT
disruption was noted in all explants from J1ECKO embryos (7/7 mice),
indicating a crucial role for endothelial Jag1 early in this process.
Jag1 can function as an antagonistic ligand to Delta-like 4 (Dll4)
in the endothelium (Benedito et al., 2009). Thus, it was important
to understand whether absence of Jag1 in the endocardium resulted
in blockade or activation of Notch signaling. Using a Notch GFP
reporter mouse line crossed to the J1ECKO mice, we found that
removal of Jag1 in the endothelium led to a loss of Notch signaling
in the endocardial cushion interface and within transformed
mesenchymal cells (Fig. 5D). J1ECKO endocardial cells (GFP–),
retained Pecam1 expression and were stacked several layers thick,
whereas the cardiac jelly remained less densely populated (Fig. 5D,
open arrow). By contrast, Notch reporter expression in vessels of
J1ECKO mice remained similar to littermate controls (Fig. 5E,
arrows). This indicates that the cardiac endothelium of J1ECKO mice
display a loss-of-function phenotype, whereas other endothelial
populations probably have compensation from additional Notch
ligands, such as Dll4.
As the majority of J1ECKO mice survive to adulthood, it suggests
an eventual compensation for the loss of Jag1, a modifier effect
from the genetic background, or incomplete deletion when EndMT
is occurring. However, this fortuitous feature resembles the
phenotype of the cardiac defects in human AGS disease and
provides a broader picture of the multiple effects of Jag1 at later
stages of cardiovascular development.
Jag1 is required for valve morphogenesis
The cardiac cushion defects present in J1ECKO and N1ECKO hearts,
as well as the link to calcific aortic valve disease in humans and
animal models, prompted a more detailed evaluation of the valves
in surviving J1ECKO mice (Acharya et al., 2011; Garg et al., 2005;
Nigam and Srivastava, 2009). As valve leaflets mature, they
initially swell up and are composed of layers of extracellular matrix
proteins, which are then remodeled and form tapered and thin
structures (Hinton and Yutzey, 2011). However, valves of J1ECKO
hearts exhibited defective remodeling, as they remained
myxomatous, or club-shaped (Fig. 3; Fig. 6).
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Fig. 4. Loss of Notch signaling impairs
EndMT in cardiac and outflow cushions.
(A-H) -Galactosidase- and Nuclear Fast Red-
stained sections of E10.5 control (A,E), J1ECKO
(B,C,F,G), and N1ECKO (D,H) mouse hearts (n=4 or
more samples evaluated per cohort). Loss of
endothelial Jag1 (B,C) leads to delayed EMT in
E10.5 cardiac cushions (magnified view indicated
by box) compared with control (A). Defects in
N1ECKO hearts (D) phenocopy those of the J1ECKO
hearts (B,C). Rounded cells (arrowheads) were
attached to the cushion interface (red arrows),
and both N1ECKO and J1ECKO hearts displayed
areas of decreased cellular density within the
cardiac jelly (B-D, open arrows) compared with
control (A). (E-H) The OFT cushions of E10.5
J1ECKO and N1ECKO mutants were also
hypocellular (F-H, open arrows) in contrast to
extensive EndMT observed in control littermates
(E, black arrows) (magnified view indicated by
box). Mesenchymal cells were transformed in
J1ECKO mutant OFT cushions mostly in places
with unrecombined endothelium, revealed by
absence of -galactosidase staining (F,G, black











To investigate the mechanism behind the abnormal valve
thickening in J1ECKO hearts, we first determined whether there were
differences in cell number (Fig. 6C,D). In neonatal animals (P0),
no significant changes in the number of cells were found in J1ECKO
valve leaflets compared with J1WT. By P10, a point at which the
valve thickening was more pronounced in J1ECKO mice, nuclear
density was lower in J1ECKO compared with J1WT valves (Fig. 6C).
We found decreased cellularity in the central region of the valve
leaflet (spongiosa) in P10 J1ECKO animals (Fig. 6D). These data
suggested that the thickening of heart valves in J1ECKO animals is
likely to be due to changes in the extracellular matrix (ECM),
rather than in cell density.
The composition, stoichiometry and organization of ECM
proteins are essential for heart valve morphogenesis and function
(Armstrong and Bischoff, 2004). As the spongiosa zone of the
valves is rich in versican (Kern et al., 2006; Yamamura et al.,
1997), we performed immunodetection analysis of the GAG
isoform on heart cross-sections at P10. In all animals examined,
versican levels, indicated by a pseudocolor scale, were increased
in the valve leaflet of J1ECKO mice compared with J1WT animals
(Fig. 7A).
To elucidate further the molecular events accounting for the
increase in versican in J1ECKO mice, we evaluated transcript
expression profiles of OFT and AV valves at P10 (Fig. 7). As
expected, Jag1 expression was decreased in both OFT and AV
valve leaflets in J1ECKO animals (by ~70%). By contrast, Notch1
and Dll4 were equivalent in J1ECKO and J1WT (Fig. 7B).
Interestingly, mRNA expression of relevant versican isoforms
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Fig. 5. Jag1 is a crucial ligand for Notch signaling during EndMT in endocardial cushions. (A) Representative images of E9.5 cardiac cushion
explants cultured for 48 hours, fixed, stained with anti-SMA (in green, arrows) and anti-PECAM1 (in red, arrowheads). Explants from J1ECKO hearts
showed a reduction in the number of transformed, SMA+ cells compared with controls (A, top panel), and exhibited sheets of Pecam1+
endothelial cells (A, arrowheads) on gel surface (A, bracket). (B) Quantification of transformed cells (calculated by SMA+ cells/total nuclei) obtained
from J1WT and J1ECKO explants. Bars represent the mean ± s.e.m. The percentage of transformed cells was significantly reduced in J1ECKO explants
(*P=0.012) compared with J1WT explants (P<0.05). Blocking Notch signaling in wild-type E9.5 explants with the -secretase inhibitor DAPT
mimicked the J1ECKO phenotype with a dose-dependent reduction of transformed cells (arrowheads in A, lower panels). (C) Quantification of
transformed cells from explants exposed to either vehicle (DMSO) or DAPT for 48 hours after isolation from E9.5 wild-type embryos. Bars represent
the mean ± s.e.m. Although the P-value of 0.09 did not reach significance by one-way ANOVA owing to increased variance in the 10 M DAPT-
treated group, application of the Bonferroni correction with an adjusted P-value (P=0.0167) to the pairwise t-test showed a significant difference
between the 50 M DAPT-treated group (*P=0.009) and DMSO vehicle-only control. For AV explants for each group, n=4-5 from different litters of
20- to 28-somite embryos. (D) Evaluation of Notch signaling in J1WT and J1ECKO hearts using GFP reporter from TNR1 transgenic crosses. Cardiac
cushions at E10.5 showed prominent Notch activity (green) in J1WT mice (arrows) and low levels of Pecam1 (red). By contrast, cushions from J1ECKO
exhibited high levels of Pecam1 (red) and a conspicuous absence of Notch reporter (green). (E) When the carotid artery (ca) and cardinal vein (cv)
from the same animals were evaluated, no significant differences in Notch reporter levels/location (green) were noted between J1WT and J1ECKO












(V0/V2 and V1) revealed no significant variability in levels
associated with Jag1 deletion (Fig. 7C). This observation indicates
that increased versican in J1ECKO valves cannot be accounted for
by overexpression of the proteoglycan. We then focused on
alterations in post-translational processing of versican by
evaluating relevant proteases and their inhibitors. The
metalloproteases Adamts1 and Adamts9 are known to cleave
versican physiologically, and Timp3 inhibits both proteases
(Rodríguez-Manzaneque et al., 2002; Sandy et al., 2001). All three
molecules are expressed in the heart at the pertinent time points
(Kern et al., 2007; Thai and Iruela-Arispe, 2002). In J1ECKO mice,
Timp3 showed a consistent, yet low increase in expression
compared with J1WT. Adamts1 was not statistically different
between mutant and controls. By contrast, Adamts9 expression was
significantly reduced in both OFT and AV valves of J1ECKO mice
(Fig. 7D). Thus, it appears that the accumulation of versican in
J1ECKO valves is likely to be due to limited versican turnover and
deficient valve remodeling.
To confirm these findings, we performed immunostaining of
valves with antibodies that recognize a neoepitope sequence of
versican (DPEAAE) generated after cleavage by matrix
metalloproteases, including Adamts (Sandy et al., 2001; Somerville
et al., 2003). Cleaved versican in J1WT valves was weak, but was
detected throughout the leaflet. By contrast, processed versican was
mainly noted in the peripheral areas of J1ECKO valves (Fig. 7E).
Thus, Jag1 deletion in the endothelium results in decreased
Adamts9 and defects in versican degradation, leading to arrested
valve remodeling and myxomatous valves.
Cartilage nodules and calcification in adult J1ECKO
valves
Given that sudden lethality was observed in adult J1ECKO mice and
that Notch1 mutations are linked to aortic valve calcification (Garg
et al., 2005), we further examined valves in mutant and control
littermates at several adult stages (5-13 months). Histological analysis
revealed increased OFT valve leaflet width (Fig. 8A, bracket).
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Fig. 6. Cardiac valve abnormalities in J1ECKO animals. (A,B) H&E-stained cardiac valves from J1WT and J1ECKO neonates. (A) The AV valves
(tricuspid and mitral) of neonatal J1ECKO mice display a lack of remodeling and thickened valves compared with littermate controls (A, arrows). (B)
Aortic valves of P1 J1WT hearts are functionally compliant, keeping blood from returning to the lower compartment (B, arrowhead), in contrast to
thickened valves from J1ECKO mice (B, arrow). Inadequate valve remodeling is evident in J1ECKO hearts in the P10 aortic valves (B, arrows). (C) Nuclear
density of valves from J1WT and J1ECKO P0 and P10 neonates. No difference in the number of nuclei was observed in J1WT (n=10) and J1ECKO (n=8)
neonates; however, nuclear density appeared decreased in J1ECKO valves (n=4) compared with J1WT (n=4) by P10. Horizontal bars represent the
mean. (D) DAPI staining of cardiac valves at P10. The graphs below correspond to pixels intensity counts (maximum 250) performed by Zen
software. Each peak in the graph represents a single nucleus. Seven nuclei are detected in J1WT valve width (100 m, one red arrow beneath
graph). The larger valves of J1ECKO mice showed similar cellular density, in this case ten nuclei in a 200 m thick valve (two red arrows beneath











Interestingly, we also detected the presence of cartilage nodules (red
arrowheads) and bone (black arrowheads) in the annulus (Fig. 8A,
dotted circle) and/or in the body of aortic valve leaflets (Fig. 8A).
Even though the animals exhibited no outward signs of disease, we
found a 50% frequency (5/10 J1ECKO mice, 0/10 controls) of
chondrogenic nodules or bone tissue in J1ECKO animals, whereas no
such abnormalities were noted in Cre-negative littermates. Von Kossa
and Alizarin Red staining of heart sections confirmed bone dysplasia
and high levels of calcium deposition in the valves of adult J1ECKO
animals (Fig. 8B, black arrowhead; supplementary material Fig. S1).
Calcium deposits were more evident in the annulus, rather than in the
leaflet of the valves (Fig. 8B).
To determine the cellular origin of the abnormal tissue, we
performed lineage analysis of VE-Cad-Cre;R26R animals.
Although it is well accepted that valve fibroblasts originate from
the endothelium, lineage analysis in older adult mice has not been
performed. Both the annulus and valve leaflets were largely
positive for Cre activity, denoted by -galactosidase staining (Fig.
8C, red arrows). Thus, the majority of cells located in both the
leaflets and the annulus are derived from an endothelial progenitor
and in J1ECKO mice are, therefore, Jag1 deficient. These data
strongly support that, in addition to its role in early heart
development, Jag1 signaling is required postnatally to prevent
valve calcification (Fig. 9).
DISCUSSION
The results of this study demonstrate a crucial role for Jag1 in the
endocardium during heart development and provide a new
clinically relevant model for the human cardiac phenotypes
associated with AGS and valve disease. Loss of Jag1 or Notch1 in
the endothelium using VE-Cadherin-Cre, led to disruption of
EndMT in the AV canal and OFT cushions. In addition, 50% of the
mutants that survived to adulthood exhibited valve defects and
calcification. Together, these data indicate that endothelial Jag1
affects distinct temporal stages of heart development through
diverse and non-overlapping mechanisms.
The inherent complexity of a multisystem syndrome such as
AGS makes the identification of the cells responsible and the
treatment of the disease problematic. Other endothelial-specific
Jag1 knockout mice succumb to lethality by E10.5, similar to
global inactivation of Jag1 (Benedito et al., 2009; High et al., 2008;
Xue et al., 1999). Although these endothelial cell Jag1-deficient
mice demonstrated pericardial edema and defects in smooth muscle
cell recruitment, major cardiac defects, such as those associated
with AGS, were not found in those models owing to the early
lethality (Nemir and Pedrazzini, 2008). Although much has been
done to develop a mouse model that faithfully reproduces AGS,
introduction of the human mutations in mice do not yield the
clinical features of AGS. Specifically, mice with loss of
heterozygosity or harboring missense mutations of Jag1 exhibit
only a few characteristics of AGS with very mild severity or weak
penetration (Vrijens et al., 2006; Xue et al., 1999). Only doubly
heterozygous Jag1;Notch2 mice reconstitute a more human-like
AGS model that shows both major hepatic and cardiac defects
(McCright et al., 2002). As a result of its later deletion, the J1ECKO
model presented here recapitulates, exclusively, many of the
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Fig. 7. Valve thickening in J1ECKO animals is associated with increased versican deposition and decreased versican cleavage. (A) Versican
GAG immunodetection (green) of valves from P10 mice is present throughout the J1ECKO valve leaflet whereas it is mainly near the periphery of
the J1WT leaflet. A pseudocolor scale used for GAG detection revealed increased staining intensity in J1ECKO valves, as illustrated by the increase of
warm range pixels (orange to white), compared with J1WT. (B-D) qPCR analysis of OFT and AV valves mRNA at P10. mRNA levels were normalized
using Hprt as a housekeeping gene. The data are expressed relative to mean CT of control animals (J1WT n=5; J1ECKO n=5). (B) Notch signaling
pathway-related genes. Jagged 1 mRNA is significantly decreased in J1ECKO OFT and AV valves compared with J1WT, whereas Notch1 and Dll4 do
not vary. (C) Versican isoforms (V0/V2 and V1) mRNA expression showed no change when comparing valves from J1WT and J1ECKO mice. (D)
Expression of versican-processing proteases and inhibitors. Only minor changes were detected in Adamts1 expression, whereas Adamts9 expression
was significantly decreased in both J1ECKO OFT and AV valves. Although not statistically significant, the inhibitor Timp3 was increased in the J1ECKO
valves. (E) Versican neoepitope DPEAAE immunodetection of P10 valves. Immunostaining intensity was lower in J1ECKO valves compared with J1WT.












cardiac defects of AGS, avoiding potential complications caused
by liver dysfunction. In fact, as an autosomal dominant disorder,
the phenotype displayed in human AGS appears to be mimicked in
mice by progressive loss of function when it is manifested after
E10.5, a time when complete absence of Jag1 in the endothelium
is lethal (High et al., 2008).
The observation of abnormal patterning, branching and fragility
of the coronary vessels shown in neonatal and adult J1ECKO mice
is novel and one not previously reported in other surviving Jag1
mutant mice (Benedito et al., 2009; McCright et al., 2002; Vrijens
et al., 2006). As already mentioned, most Jag1 knockout mice die
before the coronary plexus starts forming at E11.5 (Benedito et al.,
2009; High et al., 2008; Xue et al., 1999). Because the coronary
vessels originate primarily from VE-Cadherin-positive endothelial
sprouts of the sinus venosus, with a secondary source coming from
the endocardium, and because Jag1 is known to be expressed in
both areas, our data suggest a role for Jag1 in the proper formation
and integrity of the coronary vasculature (de la Pompa and Epstein,
2012; Penton et al., 2012; Red-Horse et al., 2010). The increased
vessel branching demonstrated by CT imaging was fairly
unexpected and intriguing, as inducible loss of endothelial Jag1 led
to decreased branching in postnatal retinas (Benedito et al., 2009).
Additionally, recent studies demonstrate a requirement of
endothelial Jag1 for mural cell development and differentiation,
which warrants a thorough examination of these vessels and their
smooth muscle and pericyte coverage (High et al., 2008; Liu et al.,
2009; Scheppke et al., 2012).
The contribution of the Notch receptor and its downstream
targets to EndMt has long been acknowledged; however, the
Notch ligand and the specific cell type responsible for these
events had not been definitively identified (de la Pompa and
Epstein, 2012). Although Dll4 mutants display mild EndMT
defects in the outflow tract cushions (Trindade et al., 2008), the
intensity and features displayed with the absence of Jag1 clearly
indicate that this is the most relevant ligand in EndMT.
Interestingly, Jag1 has been associated with EMT in multiple
systems. For example, in cultured epithelial cells from normal
tissues and breast cancer lines, as well as human microvascular
endothelial cells, Jag1 has been implicated in the cascade of
signaling required for EMT (Leong et al., 2007; Noseda et al.,
2004; Zavadil et al., 2004). In the secondary heart field, Notch
and Jag1 regulate Fgf8 expression in a non-cell-autonomous
manner during OFT EndMT (High et al., 2009).
The present study also offers insights into the role of Jag1 in
valve remodeling. Mutations in NOTCH1 have been previously
associated with congenital aortic valve malformations and
calcification (de la Pompa and Epstein, 2012; Garg et al., 2005;
MacGrogan et al., 2011). In addition, there is accumulating
evidence that Notch signaling inhibits aortic valve calcification
(Acharya et al., 2011; Garg et al., 2005; Nigam and Srivastava,
2009). Nonetheless, the specific contribution of Notch signaling to
valve organization and ECM remodeling was unclear. Our findings
indicate that Jag1 is a crucial Notch ligand in valves and its
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Fig. 8. Jagged 1 deletion in endothelial cells is associated with
calcification of adult heart valves. (A,B) J1WT and J1ECKO mice
between 5 and 13 months old were randomly selected (J1WT n=10;
J1ECKO n=10). (A) H&E staining of valves showed cartilage-like nodules
(A, red arrowhead) and bone tissue (A, black arrowhead) in OFT and AV
valves of J1ECKO adult mice. These features were absent from valves of
J1WT mice. Also, note that OFT valve leaflets appeared thicker in J1ECKO
compared with J1WT animals (A, brackets). The annulus is shown as a
dashed circle. (B) Von Kossa staining confirmed the presence of calcium
accumulation in the bone-like tissue observed in J1ECKO valves,
particularly in the annulus region (black arrowheads). (C) -
Galactosidase staining of valves from adult VE-Cadherin-Cre;R26R
animals (high magnification images indicated by black and red boxes)
revealed Cre activity in both valve annulus and leaflets (red arrows),
highlighting the endothelial origin of cells that populate these regions.
-Galactosidase-negative cells are noted by black arrows. OFT and J1WT
AV valve leaflets are shown from a three-leaflet view, whereas the
J1ECKO AV valve is a four-chamber view of the section. A, annulus; L,
leaflet. Scale bars: 100 m.
Fig. 9. Contribution of Jag1 to cardiac development. At mid-
gestation (E9.5-14.5), Jag1 is crucial for EndMT with essential
contributions to morphogenesis of the interventricular septum and AV,
aortic and pulmonary valves. In addition, Jag1 regulates valve












inactivation results in a high incidence of valve calcification.
Furthermore, we found an imbalance in versican cleavage that
could be explained by reduced expression in Adamts9, the gene
encoding a relevant protease for versican processing and turnover.
Interestingly, mice heterozygous for Adamts9 exhibit reduced
versican cleavage, myxomatous valves, and development of
cartilaginous valve nodules (Kern et al., 2010). The adequate
balance of matrix proteins in valve remodeling is essential to its
morphogenesis and function. Mice lacking a specific subset of
ECM molecules succumb to lethality associated with valve disease
(for a review, see Hinton and Yutzey, 2011).
The findings presented here indicate that, at least in the valves,
Jag1 is an important regulator of ECM organization that is crucial
for valve compliance. As determining the factors involved in
congenital heart malformations and valve disease is of high clinical
relevance, these findings should provide new avenues of
investigation, while answering several long-standing questions
about the role of Jag1 in heart development and disease.
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